Sector warns of potential ‘high human cost’ of limiting medicinal cannabis access by Steve Jones February 16, 2026June 8, 2026 Industry leaders have spoken of the “high human cost” of limiting access to medicinal cannabis as […]
Industry calls for reform agenda focused on ‘evolution’ that preserves patient access by Steve Jones February 12, 2026June 8, 2026
New cultivator plots a different path to avoid the perils of ‘over expansion’ by Steve Jones February 12, 2026February 12, 2026
News in brief: MedReleaf expands product range; Bioxyne receives first psilocybin order; Greencare names medical lead by Steve Jones February 11, 2026June 8, 2026
Hale Farm hit with ODC fine for alleged licence breach by Steve Jones February 11, 2026February 11, 2026
Deadline draws near for nominations for inaugural Dan Haslam award by Steve Jones February 10, 2026June 8, 2026
Cannim liquidator draws up timeframe for potential litigation and court-ordered director examinations by Steve Jones February 10, 2026February 10, 2026
Tensions run high as creditors vote to wind up Cannim Group by Steve Jones February 5, 2026February 5, 2026
Spring Sciences Australia still weighing up IPO and funding options after ‘tough’ 2025 by Adam Sheldon February 5, 2026February 5, 2026
Biortica executive quits cannabis to return to pharma sector by Steve Jones February 4, 2026February 5, 2026
